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Introduction
Both cardiac positron emission tomography (PET) and
cardiac magnetic resonance (CMR) imaging allow assess-
ment of myocardial perfusion and scar in patients with
suspected or previously diagnosed ischemic heart disease.
There are no clinical studies that have directly compared
these two modalities.
Purpose
In this prospective study, we sought to assess the concord-
ance of CMR and PET in detecting the burden of myocar-
dial ischemia and scar. We also assessed the prognostic
association of both modalities with cardiac death or acute
myocardial infarction (AMI).
Methods
Consecutive patients who underwent stress PET Rubid-
ium perfusion were prospectively enrolled to undergo
stress CMR for assessment of ischemia and infarction.
Sum rest and sum stress scores were qualitatively graded
using a 16-segment model in both PET and CMR. CMR
protocol consisted of cine steady-state free precession
imaging for left ventricular function, rest and adenosine-
stress first pass perfusion at 0.075 mmol/kg, and late
gadolinium enhancement (LGE) imaging for myocardial
scar.
Results
Ninety patients were enrolled and underwent CMR within
60 days of the PET. Mean age was 61 years and 60% were
male. Thirty-one had a significant reversible perfusion
defect(ReVPD)seen on stress CMR. Concordance rate for
presence of ReVPD was 71% (see Table 1). For the 26
patients with discordant findings for perfusion, 23 (88%)
patients were noted to have a RevPD by CMR. Concord-
ance rate for the presence of myocardial scar was 71%
(Table 2). In the 26 patients with discordant findings for
scar, 24 (92%) patients were noted to have subendocar-
dial scar by CMR. At a medium follow-up of 3.0 years
(IQR 2.2 years), RevPD by both PET and CMR were asso-
ciated with all major adverse events (PET: HR 2.7, P =
0.05; CMR: HR 6.9, P < 0.001). With absence of RevPD
and absence of scar, PET and CMR were associated with a
negative hard-event (cardiac death or acute myocardial
infarction) rate of 96% and 99%, respectively. Among the
25 patients with abnormal CMR (reversible defect or scar)
but normal PET, there were 3 cardiac deaths and 3 AMIs
during the follow-up.
Conclusion
In this pilot study we found moderate concordance
between CMR and PET. The absence of RevPD and scar on
either modality was associated with a good short term
prognosis. Patients who had an abnormal CMR but nor-
mal PET had an increased incidence of major cardiac
events including AMI and death.
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Table 1: Detection of reversible perfusion defects on PET and CMR
Patients with no reversible perfusion 
defect on stress CMR
Patients with reversible perfusion defect 
on stress CMR
Patients with no reversible perfusion defect on 
PET
56 23
Patients with reversible perfusion defect on 
PET
3 8
Table 2: Detection of myocardial scar by PET and CMR
Patients with no scar on CMR Patients with scar on CMR
Patients with no scar on PET 59 24
Patients with Scar on PET 2 4Page 2 of 2
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